Circulating microRNAs as biomarkers for metabolic disease

Best Practice and Research: Clinical Endocrinology and Metabolism

Volumn 30, Issue 5, 2016, Pages 591-601

  Párrizas, Marcelina ^a   Novials, Anna ^a  

^a INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

Author keywords

biomarkers; diabetes mellitus; diagnosis; metabolic syndrome; microRNAs; obesity

Indexed keywords

GLUCOSE; LIPID; MICRORNA; MICRORNA 122; MICRORNA 192; MICRORNA 193B; MICRORNA 33; MICRORNA 375; MICRORNA LET 7; UNCLASSIFIED DRUG; BIOLOGICAL MARKER;

ADIPOSE TISSUE; CELL DIFFERENTIATION; CHOLESTEROL METABOLISM; CLINICAL PRACTICE; DIABETES MELLITUS; DIABETIC NEPHROPATHY; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HUMAN; INFLAMMATION; INSULIN RELEASE; LIPID BLOOD LEVEL; LIPID METABOLISM; METABOLIC DISORDER; PANCREAS ISLET; REVIEW; RNA METABOLISM; TISSUE INJURY; BLOOD; GENETICS; METABOLISM;

BIOMARKERS; HUMANS; METABOLIC DISEASES; MICRORNAS;

EID: 84995468151     PISSN: 1521690X     EISSN: 15321908     Source Type: Journal    
DOI: 10.1016/j.beem.2016.08.001     Document Type: Review

References (99)

1. [1] Wild, S., Roglic, G., Green, A., et al. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 27 (2004), 1047–1053.
2. [2] Groop, L., Pociot, F., Genetics of diabetes-are we missing the genes or the disease?. Mol Cell Endocrinol 382 (2014), 726–739.
3. [3] DeFronzo, R., Abdul-Ghani, M., Assessment and treatment of cardiovascular risk in prediabetes: impaired glucose tolerance and impaired fasting glucose. Am J Cardiol 108 (2011), 3B–24B.
4. [4] Vazzana, N., Ranalli, P., Cuccurullo, C., et al. Diabetes mellitus and thrombosis. Thromb Res 129 (2012), 371–377.
5. [5] Rubin, D.J., Hospital readmission of patients with diabetes. Curr Diabet Rep, 15, 2015, 17.
6. [6] Thorn, L.M., Forsblom, C., Fagerudd, J., et al. Metabolic syndrome in type 1 diabetes: association with diabetic nephropathy and glycemic control (the FinnDiane study). Diabetes Care 28 (2005), 2019–2024.
7. [7] Malik, V.S., Willett, W.C., Hu, F.B., Global obesity: trends, risk factors and policy implications. Nat Rev Endocrinol 9 (2013), 13–27.
8. [8] Keller, M.P., Choi, Y., Wang, P., et al. A gene expression network model of type 2 diabetes links cell cycle regulation in islets with diabetes susceptibility. Genome Res 18 (2008), 706–716.
9. [9] Glass, C.K., Olefsky, J.M., Inflammation and lipid signaling in the etiology of insulin resistance. Cell Metab 15 (2012), 635–645.
10. [10] Mitrakou, A., Kelley, D., Mokan, M., et al. Role of reduced suppression of glucose production and diminished early insulin release in impaired glucose tolerance. N. Engl J Med 326 (1992), 22–29.
11. [11] Fajans, S.S., Bell, G.I., MODY: history, genetics, pathophysiology, and clinical decision making. Diabetes Care 34 (2011), 1878–1884.
12. [12] Vaisse, C., Clement, K., Guy-Grand, B., et al. A frameshift mutation in human MC4R is associated with a dominant form of obesity. Nat Genet 20 (1998), 113–114.
13. [13] Gabcova-Balaziova, D., Stanikova, D., Vohnout, B., et al. Molecular-genetic aspects of familial hypercholesterolemia. Endocr Regul 49 (2015), 164–181.
14. [14] Müller, G., Microvesicles/exosomes as potential novel biomarkers of metabolic diseases. Diabetes Metab Syndr Obes 5 (2012), 247–282.
15. [15] Reddy, M.A., Zhang, E., Natarajan, R., Epigenetic mechanisms in diabetic complications and metabolic memory. Diabetologia 58 (2015), 443–455.
16. [16] Cleland, S.J., Cardiovascular risk in double diabetes mellitus-when two worlds collide. Nat Rev Endocrinol 8 (2012), 476–485.
17. [17] Mendell, J.T., Olson, E.N., MicroRNAs in stress signaling and human disease. Cell 148 (2012), 1172–1187.
18. Chen, X., Ba, Y., Ma, L., et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 18 (2008), 997–1006.
19. [19] Hunter, M.P., Ismail, N., Zhang, X., et al. Detection of microRNA expression in human peripheral blood microvesicles. Plos One, 3, 2008, e3694.
20. [20] Guay, C., Regazzi, R., Circulating microRNAs as novel biomarkers for diabetes mellitus. Nat Rev Endocrinol 9 (2013), 513–521.
21. [21] Arroyo, J.D., Chevillet, J.R., Kroh, E.M., et al. Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. Proc Natl Acad Sci USA 108 (2011), 5003–5008.
22. [22] Vickers, K.C., Palmisano, B.T., Shoucri, B.M., et al. MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins. Nat Cell Biol 13 (2011), 423–433.
23. Valadi, H., Ekström, K., Bossios, A., et al. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol 9 (2007), 654–659.
24. [24] Wang, Y., Li, Y., Wang, X., et al. Circulating miR-130b mediates metabolic crosstalk between fat and muscle in overweight/obesity. Diabetologia 56 (2013), 2275–2285.
25. [25] Fong, M.Y., Zhou, W., Liu, L., et al. Breast-cancer-secreted miR-122 reprograms glucose metabolism in premetastatic niche to promote metastasis. Nat Cell Biol 17 (2015), 183–194.
26. Hergenreider, E., Heydt, S., Tréguer, K., et al. Atheroprotective communication between endothelial cells and smooth muscle cells through miRNAs. Nat Cell Biol 14 (2012), 249–256.
27. Krutzfeldt, J., Rajewsky, N., Braich, R., et al. Silencing of microRNAs in vivo with “antagomirs”. Nature 438 (2005), 685–689.
28. [28] Esau, C., Davis, S., Murray, S.F., et al. miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting. Cell Metab 3 (2006), 87–98.
29. [29] Elmen, J., Lindow, M., Silahtaroglu, A., et al. Antagonism of microRNA-122 in mice by systemically administered LNA-antimiR leads to up-regulation of a large set of predicted target mRNAs in the liver. Nucleic Acids Res 36 (2008), 1153–1162.
30. [30] Elmen, J., Lindow, M., Schutz, S., et al. LNA-mediated microRNA silencing in non-human primates. Nature 452 (2008), 896–899.
31. [31] Masyuk, A.I., Masyuk, T.V., Larusso, N.F., Exosomes in the pathogenesis, diagnostics and therapeutics of liver diseases. J Hepatol 59 (2013), 621–625.
32. [32] Rayner, K.J., Suarez, Y., Davalos, A., et al. MiR-33 contributes to the regulation of cholesterol homeostasis. Science 328 (2010), 1570–1573.
33. [33] Horie, T., Ono, K., Horiguchi, M., et al. MicroRNA-33 encoded by an intron of sterol regulatory element-binding protein 2 (Srebp2) regulates HDL in vivo. Proc Natl Acad Sci USA 107 (2010), 17321–17326.
34. [34] Najafi-Shoushtari, S.H., Kristo, F., Li, Y., et al. MicroRNA-33 and the SREBP host genes cooperate to control cholesterol homeostasis. Science 328 (2010), 1566–1569.
35. [35] Price, N.L., Holtrup, B., Kwei, S.L., et al. SREBP-1c/MicroRNA 33b genomic loci control adipocyte differentiation. Mol Cell Biol 36 (2016), 1180–1193.
36. [36] Ouimet, M., Ediriweera, H.N., Mahesh Gundra, U., et al. MicroRNA-33-dependent regulation of macrophage metabolism directs immune cell polarization in atherosclerosis. J Clin Investig 125 (2015), 4334–4348.
37. [37] Kulyté, A., Belarbi, Y., Lorente-cebrián, S., et al. Additive effects of miRNAs and transcription factors on CCL2 production in human white adipose tissue. Diabetes 63 (2014), 1248–1258.
38. [38] Cobos Jiménez, V., Bradley, E.J., Willemsen, A.M., et al. Next-generation sequencing of microRNAs uncovers expression signatures in polarized macrophages. Physiol Genom 46 (2014), 91–103.
39. [39] Sun, L., Xie, H., Mori, M., et al. MiR-193b-365, a brown fat enriched microRNA cluster, is essential for brown fat differentiation. Nat Cell Biol 13 (2012), 958–965.
40. [40] Frost, R.J., Olson, E.N., Control of glucose homeostasis and insulin sensitivity by the let-7 family of microRNAs. Proc Natl Acad Sci USA 108 (2011), 21075–21080.
41. Zhu, H., Shyh-Chang, N., Segrè, A.V., et al. The Lin28/let-7 axis regulates glucose metabolism. Cell 147 (2011), 81–94.
42. [42] Krutzfeldt, J., Rosch, N., Hausser, J., et al. MicroRNA-194 is a target of transcription factor 1 in adult liver and controls expression of frizzled-6. Hepatology 55 (2012), 98–107.
43. [43] Deshpande, S.D., Putta, S., Wang, M., et al. Transforming growth factor-β-induced cross talk between p53 and a microRNA in the pathogenesis of diabetic nephropathy. Diabetes 62 (2013), 3151–3162.
44. [44] Poy, M.N., Eliasson, L., Krutzfeldt, J., et al. A pancreatic islet-specific microRNA regulates insulin secretion. Nature 432 (2004), 226–230.
45. [45] Latreille, M., Herrmanns, K., Renwick, N., et al. miR-375 gene dosage in pancreatic β-cells: implications for regulation of β-cell mass and biomarker development. J Mol Med 93 (2015), 1159–1169.
46. [46] Dooley, J., Garcia-Perez, J.E., Sreenivasan, J., et al. The microRNA-29 family dictates the balance between homeostatic and pathological glucose handling in diabetes and obesity. Diabetes 65 (2016), 53–61.
47. [47] Xu, H., Guo, S., Li, W., et al. The circular RNA Cdr1as, via miR-7 and its targets, regulates insulin transcription and secretion in islet cells. Sci Rep, 5, 2015, 12453, 10.1038/srep12453.
48. [48] Wang, Y., Liu, J., Liu, C., et al. MicroRNA-7 regulates the mTOR pathway and proliferation in adult pancreatic beta-cells. Diabetes 62 (2013), 887–895.
49. [49] Ortega, F.J., Mercader, J.M., Moreno-Navarrete, J.M., et al. Profiling of circulating microRNAs reveals common microRNAs linked to type 2 diabetes that change with insulin sensitization. Diabetes Care 37 (2014), 1375–1383.
50. [50] Párrizas, M., Brugnara, L., Esteban, Y., et al. Circulating miR-192 and miR-193b are markers of prediabetes and are modulated by an exercise intervention. J Clin Endocrinol Metabol 100 (2015), E407–E415.
51. [51] Pescador, N., Pérez-Barba, M., Ibarra, J.M., et al. Serum circulating microRNA profiling for identification of potential type 2 diabetes and obesity biomarkers. Plos One, 8, 2013, e77251.
52. [52] Prabu, P., Rome, S., Sathishkumar, C., et al. Circulating MiRNAs of “Asian Indian Phenotype” identified in subjects with impaired glucose tolerance and patients with type 2 diabetes. Plos One, 10, 2015, e0128372.
53. [53] Santovito, D., De Nardis, V., Marcantonio, P., et al. Plasma exosome microRNA profiling unravels a new potential modulator of adiponectin pathway in diabetes: effect of glycemic control. J Clin Endocrinol Metabol 99 (2014), E1681–E1685.
54. [54] Wang, C., Wan, S., Yang, T., et al. Increased serum microRNAs are closely associated with the presence of microvascular complications in type 2 diabetes mellitus. Sci Rep, 6, 2016, 20032.
55. [55] Yang, Z., Chen, H., Si, H., et al. Serum miR-23a, a potential biomarker for diagnosis of pre-diabetes and type 2 diabetes. Acta Diabetol 51 (2014), 823–831.
56. Zampetaki, A., Kiechl, S., Drozdov, I., et al. Plasma microRNA profiling reveals loss of endothelial miR-126 and other microRNAs in type 2 diabetes. Circ Res 107 (2010), 810–817.
57. [57] Jansen, F., Wang, H., Przybilla, D., et al. Vascular endothelial microparticles-incorporated microRNAs are altered in patients with diabetes mellitus. Cardiovasc Diabetol, 15, 2016, 49.
58. [58] Lv, C., Zhou, Y.-H., Wu, C., et al. The changes in miR-130b levels in human serum and the correlation with the severity of diabetic nephropathy. Diabetes Metab Res Rev 31 (2015), 717–724.
59. [59] Flowers, E., Aouizerat, B.E., Abbasi, F., et al. Circulating microRNA-320a and microRNA-486 predict thiazolidinedione response: moving towards precision health for diabetes prevention. Metabolism 64 (2015), 1051–1059.
60. [60] Wang, R., Hong, J., Cao, Y., et al. Elevated circulating microRNA-122 is associated with obesity and insulin resistance in young adults. Eur J Endocrinol 172 (2015), 291–300.
61. [61] Ortega, F.J., Mercader, J.M., Catalán, V., et al. Targeting the circulating microRNA signature of obesity. Clin Chem 59 (2013), 781–792.
62. [62] Prats-Puig, A., Ortega, F.J., Mercader, J.M., et al. Changes in circulating microRNAs are associated with childhood obesity. J Clin Endocrinol Metabol 98 (2013), E1655–E1660.
63. [63] Tan, Y., Ge, G., Pan, T., et al. A pilot study of serum microRNAs panel as potential biomarkers for diagnosis of nonalcoholic fatty liver disease. Plos One, 9, 2014, e105192.
64. [64] Pirola, C.J., Fernández Gianotti, T., Castaño, G.O., et al. Circulating microRNA signature in non-alcoholic fatty liver disease: from serum non-coding RNAs to liver histology and disease pathogenesis. Gut 64 (2015), 800–812.
65. [65] Bijkerk, R., Duijs, J.M.G.J., Khairoun, M., et al. Circulating microRNAs associate with diabetic nephropathy and systemic microvascular damage and normalize after simultaneous pancreas-kidney transplantation. Am J Transplant 15 (2015), 1081–1090.
66. [66] Nielsen, L.B., Wang, C., Sørensen, K., et al. Circulating levels of microRNA from children with newly diagnosed type 1 diabetes and healthy controls: evidence that miR-25 associates to residual beta-cell function and glycaemic control during disease progression. Exp Diabetes Res, 2012, 2012, 896362.
67. [67] Osipova, J., Fischer, D.-C., Dangwal, S., et al. Diabetes-associated microRNAs in pediatric patients with type 1 diabetes mellitus: a cross-sectional cohort study. J Clin Endocrinol Metabol 99 (2014), E1661–E1665.
68. [68] Yamada, H., Suzuki, K., Ichino, N., et al. Associations between circulating microRNAs and non-alcoholic fatty liver. Clin Chim Acta 424 (2013), 99–103.
69. [69] Can, U., Buyukinan, M., Yerlikaya, F.H., The investigation of circulating microRNAs associated with lipid metabolism in childhood obesity. Pediatr Obes 11 (2016), 228–234.
70. [70] Martino, F., Carlomosti, F., Avitabile, D., et al. Circulating miR-33a and miR-33b are up-regulated in familial hypercholesterolaemia in paediatric age. Clin Sci 129 (2015), 963–972.
71. [71] Wu, Q., Li, J.V., Seyfried, F., et al. Metabolic phenotype-microRNA data fusion analysis of the systemic consequences of Roux-en-Y gastric bypass surgery. Int J Obes 39 (2015), 1126–1134.
72. [72] Karolina, D.S., Tavintharan, S., Armugam, A., et al. Circulating miRNA profiles in patients with metabolic syndrome. J Clin Endocrinol Metabol 97 (2012), E2271–E2276.
73. [73] Wang, K., Zhang, S., Marzolf, B., et al. Circulating microRNAs, potential biomarkers for drug-induced liver injury. Proc Natl Acad Sci USA 106 (2009), 4402–4407.
74. [74] Jiang, L., Huang, J., Chen, Y., et al. Identification of several circulating microRNAs from a genome-wide circulating microRNA expression profile as potential biomarkers for impaired glucose metabolism in polycystic ovarian syndrome. Endocrine 53 (2016), 280–290.
75. [75] Chien, H.-Y., Chen, C.-Y., Chiu, Y.-H., et al. Differential microRNA profiles predict diabetic nephropathy progression in Taiwan. Int J Med Sci 13 (2016), 457–465.
76. [76] Jia, Y., Guan, M., Zheng, Z., et al. miRNAs in urine extracellular vesicles as predictors of early-stage diabetic nephropathy. J Diabetes Res, 2016, 2016, 7932765.
77. [77] Kong, L., Zhu, J., Han, W., et al. Significance of serum microRNAs in pre-diabetes and newly diagnosed type 2 diabetes: a clinical study. Acta Diabetol 48 (2011), 61–69.
78. [78] Marchand, L., Jalabert, A., Meugnier, E., et al. miRNA-375 a sensor of glucotoxicity is altered in the serum of children with newly diagnosed type 1 diabetes. J Diabetes Res, 2016, 2016, 1869082.
79. [79] Erener, S., Mojibian, M., Fox, J.K., et al. Circulating miR-375 as a biomarker of beta-cell death and diabetes in mice. Endocrinology 154 (2013), 603–608.
80. [80] Fichtlscherer, S., De Rosa, S., Fox, H., et al. Circulating microRNAs in patients with coronary artery disease. Circ Res 107 (2010), 677–684.
81. Jansen, F., Yang, X., Hoelscher, M., et al. Endothelial microparticle-mediated transfer of MicroRNA-126 promotes vascular endothelial cell repair via SPRED1 and is abrogated in glucose-damaged endothelial microparticles. Circulation 128 (2013), 2026–2038.
82. Olivieri, F., Spazzafumo, L., Bonafe, M., et al. MiR-21-5p and miR-126a-3p levels in plasma and circulating angiogenic cells: relationship with type 2 diabetes complications. Oncotarget 6 (2015), 35372–35382.
83. [83] Milagro, F.I., Miranda, J., Portillo, M.P., et al. High-throughput sequencing of microRNAs in peripheral blood mononuclear cells: identification of potential weight loss biomarkers. Plos One, 8, 2013, e54319.
84. [84] Zhu, H., Leung, S.W., Identification of microRNA biomarkers in type 2 diabetes: a meta-analysis of controlled profiling studies. Diabetologia 58 (2015), 900–911.
85. [85] Villard, Audrey, Marchand, Lucien, Thivolet, Charles, et al. Diagnostic value of cell-free circulating MicroRNAs for obesity and type 2 diabetes: a meta-analysis. J Mol Biomarkers Diagn 6 (2015), 356–372.
86. [86] Wang, K., Yuan, Y., Cho, J.-H., et al. Comparing the MicroRNA spectrum between serum and plasma. PLoS One, 7, 2012, e41561.
87. [87] Turchinovich, A., Weiz, L., Langheinz, A., et al. Characterization of extracellular circulating microRNA. Nucleic Acids Res 39 (2011), 7223–7233.
88. Blondal, T., Jensby Nielsen, S., Baker, A., et al. Assessing sample and miRNA profile quality in serum and plasma or other biofluids. Methods 59 (2013), S1–S6.
89. [89] Pritchard, C.C., Kroh, E., Wood, B., et al. Blood cell origin of circulating microRNAs: a cautionary note for cancer biomarker studies. Cancer Prev Res 5 (2012), 492–497.
90. [90] Moldovan, L., Batte, K.E., Trgovcich, J., et al. Methodological challenges in utilizing miRNAs as circulating biomarkers. J Cell Mol Med 18 (2014), 371–390.
91. [91] Mestdagh, P., Hartmann, N., Baeriswyl, L., et al. Evaluation of quantitative miRNA expression platforms in the microRNA quality control (miRQC) study. Nat Methods 11 (2014), 809–815.
92. [92] Git, A., Dvinge, H., Salmon-Divon, M., et al. Systematic comparison of microarray profiling, real-time PCR, and next-generation sequencing technologies for measuring differential microRNA expression. RNA 16 (2010), 991–1006.
93. [93] Farr, R.J., Januszewski, A.S., Joglekar, M.V., et al. A comparative analysis of high-throughput platforms for validation of a circulating microRNA signature in diabetic retinopathy. Sci Rep, 5, 2015, 10375.
94. [94] Bonner, C., Nyhan, K.C., Bacon, S., et al. Identification of circulating microRNAs in HNF1A-MODY carriers. Diabetologia 56 (2013), 1743–1751.
95. [95] Hori, S., Gambhir, S., Mathematical model identifies blood biomarker-based early Cancer detection strategies and limitations. Sci Transl Med, 3(109), 2011, ra116.
96. [96] Williams, Z., Ben-Dov, I.Z., Elias, R., et al. Comprehensive profiling of circulating microRNA via small RNA sequencing of cDNA libraries reveals biomarker potential and limitations. Proc Natl Acad Sci USA 110 (2013), 4255–4260.
97. [97] Zaharieva, I.T., Calissano, M., Scoto, M., et al. Dystromirs as serum biomarkers for monitoring the disease severity in Duchenne muscular Dystrophy. Plos One, 8, 2013, e80263.
98. [98] Raitoharju, E., Seppälä, I., Oksala, N., et al. Blood microRNA profile associates with the levels of serum lipids and metabolites associated with glucose metabolism and insulin resistance and pinpoints pathways underlying metabolic syndrome. Mol Cell Endocrinol 391 (2014), 41–49.
99. Kranendonk, M.E.G., de Kleijn, D.P.V., Kalkhoven, E., et al. Extracellular vesicle markers in relation to obesity and metabolic complications in patients with manifest cardiovascular disease. Cardiovasc Diabetol, 13, 2014, 37.